BCG for upper-tract transitional-cell carcinoma: is it safe in patients with renal compromise?
We report three cases of end-stage renal failure necessitating hemodialysis subsequent to BCG administration for the treatment of upper-urinary tract transitional-cell carcinoma in patients with a solitary kidney, one with normal renal function and two with chronic renal failure prior to BCG instillation. We discuss treatment-related issues with pertinent literature review.
Binsaleh
Saleh
S
Division of Urology, Department of Surgery, Royal Victoria Hospital, McGill University, Montréal, Québec, Canada. surgon@hotmail.com
Sircar
Kanishka
K
Elhilali
Mostafa
M
Anidjar
Maurice
M
D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology
D001500:BCG Vaccine